Lori F - Search Results

1

New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Ravot E, Lisziewicz J, Lori F. Ravot E, et al. Among authors: lori f. Drugs. 1999 Dec;58(6):953-63. doi: 10.2165/00003495-199958060-00001. Drugs. 1999. PMID: 10651384 Review.

2

Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag.

Lori F, Lisziewicz J, Smythe J, Cara A, Bunnag TA, Curiel D, Gallo RC. Lori F, et al. Gene Ther. 1994 Jan;1(1):27-31. Gene Ther. 1994. PMID: 7584056

3

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.

Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC. Lori F, et al. Science. 1994 Nov 4;266(5186):801-5. doi: 10.1126/science.7973634. Science. 1994. PMID: 7973634

4

Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.

Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M, Gallo RC. Lisziewicz J, et al. Among authors: lori f. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8000-4. doi: 10.1073/pnas.90.17.8000. Proc Natl Acad Sci U S A. 1993. PMID: 8367455 Free PMC article.

5

Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I.

Villani P, Maserati R, Regazzi MB, Giacchino R, Lori F. Villani P, et al. Among authors: lori f. J Clin Pharmacol. 1996 Feb;36(2):117-21. doi: 10.1002/j.1552-4604.1996.tb04176.x. J Clin Pharmacol. 1996. PMID: 8852387 Clinical Trial.

6

Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines.

Lisziewicz J, Sun D, Gallo RC, Ensoli B, Lori F. Lisziewicz J, et al. Among authors: lori f. Hum Gene Ther. 1996 Dec 1;7(18):2209-16. doi: 10.1089/hum.1996.7.18-2209. Hum Gene Ther. 1996. PMID: 8953311

7

Long-term suppression of HIV-1 by hydroxyurea and didanosine.

Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Lori F, et al. JAMA. 1997 May 14;277(18):1437-8. JAMA. 1997. PMID: 9145714 No abstract available.

8

Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.

De Antoni A, Foli A, Lisziewicz J, Lori F. De Antoni A, et al. Among authors: lori f. J Infect Dis. 1997 Oct;176(4):899-903. doi: 10.1086/516511. J Infect Dis. 1997. PMID: 9333147 Clinical Trial.

9

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.

Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J. Lori F, et al. AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1403-9. doi: 10.1089/aid.1997.13.1403. AIDS Res Hum Retroviruses. 1997. PMID: 9359660 Clinical Trial.

10

Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.

Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F. Foli A, et al. Among authors: lori f. AIDS. 1998 Jun 18;12(9):1113-4. AIDS. 1998. PMID: 9662215 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters